Related Experiment Video
Updated: Jul 13, 2026

Preparation of Cell-lines for Conditional Knockdown of Gene Expression and Measurement of the Knockdown Effects on E4orf4-Induced Cell Death
Published on: October 21, 2012
Adenovirus type 5 E1A-induced apoptosis in COX-2-overexpressing breast cancer cells
Takeshi Sugimoto1, Chandra Bartholomeusz, Ana M Tari
1Breast Cancer Translational Research Laboratory, The University of Texas M, D, Anderson Cancer Center, Houston, TX, USA. tks_sugimoto@yahoo.co.jp.
Introduction:
Suppression of Bcl-2 expression can overcome cellular resistance to apoptosis induced by the adenovirus type 5 gene E1A in models of ovarian and breast cancer. Celecoxib, a cyclooxygenase-2 (COX-2) inhibitor, is known to downregulate Bcl-2 expression. We hypothesized that celecoxib would enhance E1A-induced apoptosis by suppressing Bcl-2 through suppressing COX-2 expression. If successful, this strategy could represent a means of overcoming resistance to E1A gene therapy.
Methods:
We first established the cytotoxicity of celecoxib in two COX-2-overexpressing E1A-transfected breast cancer cell lines (MDA-MB-231 and MDA-MB-435) and in two low-COX-2-expressing E1A-transfected cell lines (MCF-7 (breast cancer) and SKOV3.ip1 (ovarian cancer)). We next tested whether higher sensitivity to celecoxib among these cell lines resulted from increased apoptosis by flow cytometry and western blotting. We further investigated whether suppression of Bcl-2 by celecoxib was involved in the apoptosis resulting from celecoxib treatment, and we explored whether the celecoxib-induced apoptosis in these cells depends on a COX-2 downstream pathway.
Results:
The two COX-2-overexpressing cell lines MDA-MB-231-E1A and MDA-MB-435-E1A were more sensitive to celecoxib than the corresponding control cells, but the two low-COX-2-expressing cell lines MCF-7-E1A and SKOV3.ip1-E1A were no more sensitive than control cells to celecoxib. Therefore, we used the MDA-MB-231-E1A and MDA-MB-435-E1A cells for all further experiments. In both cell lines, sub-G1 fraction was increased, or cleavage of PARP and caspase-9 were increased after 5 days of exposure to 40 microM celecoxib. However, Bcl-2 was suppressed only in the MDA-MB-435-E1A cells and not in the MDA-MB-231-E1A cells. Restoring Bcl-2 expression in the MDA-MB-435-E1A stable transfectants did not affect their sensitivity to celecoxib. However, adding prostaglandin E2 (PGE2) or PGF2alpha blunted the sensitivity to celecoxib of both E1A stable transfectants.
Conclusion:
We speculate that one mechanism by which celecoxib enhances E1A-induced apoptosis in cells that express high levels of COX-2 is through blocking PGE2 or PGF2alpha.
Insights
Celecoxib enhances adenovirus E1A-induced apoptosis in cancer cells by suppressing cyclooxygenase-2 (COX-2). This strategy may overcome resistance to E1A gene therapy by blocking prostaglandin pathways.
Area of Science:
- Oncology
- Molecular Biology
- Cancer Genetics
Background:
- Suppression of Bcl-2 can overcome resistance to adenovirus type 5 gene E1A-induced apoptosis in ovarian and breast cancers.
- Celecoxib, a cyclooxygenase-2 (COX-2) inhibitor, downregulates Bcl-2 expression.
- This study investigates if celecoxib enhances E1A-induced apoptosis by suppressing Bcl-2 via COX-2 inhibition.
Purpose of the Study:
- To determine if celecoxib enhances E1A-induced apoptosis in cancer cells.
- To investigate the role of cyclooxygenase-2 (COX-2) and Bcl-2 in celecoxib's effect.
- To explore potential mechanisms for overcoming resistance to E1A gene therapy.
Main Methods:
- Cytotoxicity assays of celecoxib in E1A-transfected breast and ovarian cancer cell lines with varying COX-2 expression.
- Flow cytometry and western blotting to assess apoptosis and Bcl-2 suppression.
- Investigating the role of prostaglandin E2 (PGE2) and PGF2alpha in celecoxib sensitivity.
Main Results:
- COX-2-overexpressing cell lines were more sensitive to celecoxib than low-COX-2-expressing lines.
- Celecoxib increased apoptosis markers (PARP, caspase-9) in sensitive cell lines.
- Bcl-2 suppression was observed only in one cell line; restoring Bcl-2 did not affect sensitivity.
- Prostaglandins PGE2 or PGF2alpha blunted celecoxib sensitivity.
Conclusions:
- Celecoxib enhances E1A-induced apoptosis in cancer cells with high COX-2 expression.
- A potential mechanism involves blocking prostaglandin pathways (PGE2/PGF2alpha).
- This approach may help overcome resistance to E1A gene therapy.
Related Concept Videos
Apoptosis
The Intrinsic Apoptotic Pathway
The Extrinsic Apoptotic Pathway
Adaptive Mechanisms in Cancer Cells
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
Adaptive Mechanisms in Cancer Cells
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
Rous Sarcoma Virus (RSV) and Cancer
RSV is a retrovirus that contains two copies of a plus-strand RNA genome. Its genome consists of four main open...
